Aug 17, 2026 · 8 min
AI chip rally collides with biotech failure and bond-market stress
Closing Bell: Chip Stocks Rise, SpaceX Gains, EyePoint Sinks
The market close shows how enthusiasm for AI-linked growth can coexist with sharp losses in drug development and rising pressure on bonds.
- 1Anthropic’s reported revenue growth helped lift AI-linked chip stocks, including SanDisk.
- 2EyePoint Pharmaceuticals plunged after its eye-disease treatment failed a late-stage trial.
- 3A bond-market sell-off pushed Treasury yields to multi-year highs as stocks moved sharply in both directions.
Don't miss
EyePoint Pharmaceuticals suffered a record drop after its eye-disease treatment failed a late-stage trial.
The brief
Carol Massar frames a market close shaped by sharply different forces: AI-linked chip stocks rallied on Anthropic’s revenue growth, while other sectors absorbed heavy losses.
SanDisk stood out among the day’s gainers as investors connected chip-stock strength to financial news surrounding Anthropic and the expanding AI economy.
Joe Deaux turns to the decliners, led by EyePoint Pharmaceuticals after its eye-disease treatment failed a late-stage trial and triggered a record drop.
The broader warning came from bonds: a sell-off pushed Treasury yields to multi-year highs, adding a second source of pressure beyond individual stocks.
The episode’s central contrast is a market rewarding AI-linked growth while punishing clinical failure and demanding higher returns from government debt.
What was said on this episode
8 statements · 4 positive · 3 negative · 1 mixed
SanDisk’s upbeat outlook contributed to a broader memory and storage stock rally.
“investors, you know, just pushing what has been a common narrative, this broader rally when it comes to memory and storage stocks after sandisk outlined an upbeat multi year financial outlook.”
Listen at 1:51
SanDisk is among the S&P 500’s top-performing stocks this year.
“SanDisk continuing to be really a high flyer this year. It is a top performing name by a wide margin in the S&P 500.”
Listen at 2:05
Investment firms for wealthy individuals have accumulated billions in SpaceX exposure.
“Investment firms for ultra wealthy individual individuals have built up billions of dollars of exposure to SpaceX.”
Listen at 2:23
More than a dozen family offices held at least $3.8 billion of SpaceX through mid-2026.
“more than a dozen family offices holding a total of at least 3.8 billion SpaceX through the first half of 2026”
Listen at 2:29
EyePoint’s experimental eye-disease treatment failed its late-stage primary endpoint.
“the drug developer said its experimental treatment for an eye disease failed to meet a primary goal in its late stage trial.”
Listen at 3:15
EyePoint’s failed trial does not necessarily end its prospects.
“that doesn't necessarily mean this is the end.”
Listen at 3:46
The 30-year Treasury yield reached its highest level since 2007.
“the 30 year yield now at the highest since 2007.”
Listen at 5:26
Risks in the bond market are increasingly tilted toward inflation.
“the balance of risk seems increasingly tilted towards inflation.”
Listen at 5:44
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Anthropic
SanDisk
EyePoint Pharmaceuticals, Inc.
United States Department of the TreasuryListen to the full episode and explore every guest, topic, and moment on PodLume.